Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Abbott Laboratories : Abbott and AbbVie Announce Investor Calls

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/14/2013 | 04:10pm CET

Abbott Park, Illinois and North Chicago - Abbott (NYSE: ABT) will announce its fourth-quarter and full-year 2012 financial results on Wednesday, Jan. 23, 2013, before the market opens.

Abbott's quarterly and annual results will include contributions from the company's former research-based pharmaceutical business, which became AbbVie on Jan. 1, 2013. While these results will be captured in a single press release, both companies will host separate conference calls to discuss their respective business results and 2013 outlooks.

Abbott will host a live webcast of the earnings conference call at 8 a.m. Central time (9 a.m. Eastern) on Jan. 23, 2013. It will be accessible through Abbott's Investor Relations website at www.abbottinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

On Wednesday, Jan. 30, 2013, AbbVie will host a live webcast at 8 a.m. Central time (9 a.m. Eastern) accessible through AbbVie's Investor Relations website at www.abbvieinvestor.com. An archived edition of the call will be available after 11 a.m. Central time.

About Abbott

Abbott (NYSE: ABT) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000 people.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott. With its 125-year history, the company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. In 2013, AbbVie employs approximately 21,000 people worldwide and markets medicines in more than 170 countries.www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Abbott Contacts:
Media:
Scott Stoffel

(847) 936-9502
Financial:
Brian Yoor

(847) 937-6343
AbbVie Contacts:
Media:
Adelle Infante

(847) 938-8745
Financial:
Larry Peepo

(847) 935-6722
distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABBOTT LABORATORIES
09:59p ABBOTT LABORATORIES : Trademark Application for "IMFED" Filed by Abbott Laborato..
09:53p ABBOTT LABORATORIES : An Application for the Trademark "TENDRIL MRI" Has Been Fi..
07:21p ABBOTT LABORATORIES : Trademark Application for "DECISIONTX" Filed by Abbott Lab..
07:11p ABBOTT LABORATORIES : An Application for the Trademark "IMFED FOR CHILDREN" Has ..
03/22 ABBOTT LABORATORIES (NYSE : ABT) Files An 8-K Creation of a Direct Financial Obl..
03/22 ABBOTT LABORATORIES : Creation of a Direct Financial Obligation or an Obligation..
03/22 ABBOTT LABORATORIES : Recent Developments in the Electrophysiology Markets
03/22 ABBOTT : Hosts Conference Call for First-Quarter Earnings
03/21 ABBOTT LABORATORIES PAKISTAN : Annual general meeting of Abbott Laboratories Pak..
03/21 ABBOTT LABORATORIES : Higher risk seen with Abbott dissolving stent
More news
Sector news : Pharmaceuticals - NEC
10:46pDJPRESS RELEASE : FDA Grants Approval for -3-
10:46pDJPRESS RELEASE : FDA Grants Approval for -2-
10:46pDJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
09:32p SEC charges two Israeli residents with Mobileye insider trading
11:53a TEVA PHARMACEUTICAL INDUSTRIES : Pharm says media reports of up to 6,000 layoffs..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02:23p Pharma Development Budgets Grow As Roche Remains A Believer
03/21 Biotechs under pressure after Trump (again) decries high drug prices
03/19 5 Dividend Investing Success Stories And 5 New Ideas Based On These Findings
03/19 Low Volatility And High Beta Stocks Prior To Last Downturn
03/16 Abbott Laboratories' (ABT) Management Presents at Barclays Capital 2017 Globa..
Advertisement
Financials ($)
Sales 2017 26 126 M
EBIT 2017 5 738 M
Net income 2017 3 771 M
Debt 2017 18 620 M
Yield 2017 2,28%
P/E ratio 2017 19,80
P/E ratio 2018 16,91
EV / Sales 2017 3,68x
EV / Sales 2018 3,42x
Capitalization 77 432 M
More Financials
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 47,8 $
Spread / Average Target 6,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Senior VP-Finance
Randel W. Woodgrift VP-Vascular, Manufacturing, Research & Development
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES16.66%77 432
JOHNSON & JOHNSON9.59%342 277
ROCHE HOLDING LTD.7.52%217 164
PFIZER INC.6.13%205 273
NOVARTIS AG0.47%194 072
MERCK & CO., INC.7.86%174 344
More Results